Low PTEN expression and overexpression of phosphorylated Akt<sup>Ser473</sup> and Akt<sup>Thr308</sup> are associated with poor overall survival in upper tract urothelial carcinoma

Weng,Wen-Hui; Yu,Kai-Jie; Li,Liang-Chen; Pang,Yeu-Jye; Chen,Ying-Tzu; Pang,See-Tong; Chuang,Cheng-Keng

doi:10.3892/ol.2020.12210

Low PTEN expression and overexpression of phosphorylated Akt^Ser473 and Akt^Thr308 are associated with poor overall survival in upper tract urothelial carcinoma

Authors:
- Wen-Hui Weng
- Kai-Jie Yu
- Liang-Chen Li
- Yeu-Jye Pang
- Ying-Tzu Chen
- See-Tong Pang
- Cheng-Keng Chuang
View Affiliations

Affiliations: Department of Chemical Engineering and Biotechnology, Graduate Institute of Biochemical and Biomedical Engineering, National Taipei University of Technology, Taipei 10608, Taiwan, R.O.C., Department of Gastroenterology, Mater Misericordiae University Hospital, Dublin D07 R2WY, Ireland, College of Medicine, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan 33302, Taiwan, R.O.C.
Published online on: October 9, 2020 https://doi.org/10.3892/ol.2020.12210
Article Number: 347
Copyright: © Weng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The PI3K/Akt signaling pathway serves an essential role in various cellular processes, including cell growth, survival, cell motility, angiogenesis and cell metabolism. Loss of PTEN expression and hyperactivation of Akt can result in tumorigenesis. Previous studies observed expression of the Akt protein and absence of the PTEN protein in bladder cancer and non‑small cell lung carcinoma tissues. The aim of the present study was to evaluate the expression status and prognostic value of PTEN and the PI3K/Akt signaling pathway in Taiwanese patients with upper tract urothelial carcinoma (UTUC). Archival formalin‑fixed, paraffin‑embedded (FFPE) tissues from 65 UTUC cases were stained via immunohistochemistry for PTEN, phosphorylated (p)Akt serine (Ser)⁴⁷³ and pAkt threonine (Thr)³⁰⁸. The expression levels of each protein were significantly correlated with clinicopathological parameters. PTEN, pAkt^Ser473 and pAkt^Thr308 protein expression levels were higher in adjacent normal tissues compared with those in tumor tissues. Cytoplasmic PTEN protein expression levels were lower in high‑stage tumors compared with those in low‑stage tumors, and nuclear and cytoplasmic pAkt^Thr308 protein expression levels were higher in high‑grade tumors compared with those in low‑grade tumors. Univariate analysis showed that high pathological tumor stage (pT2‑4) [P=0.01; hazard ratio (HR)=3.40; 95% confidence interval (CI), 1.34‑8.60], metastatic status (P=0.003; HR=3.55, 95% CI, 1.55‑8.11), low cytoplasmic PTEN protein expression levels (P=0.016; HR=3.14; 95% CI, 1.24‑7.95) and high cytoplasmic pAkt^Ser473 protein expression levels (P=0.019, HR=2.71, 95% CI, 1.18‑6.21) were predictive of poor overall survival. However, only metastatic status (P=0.031; HR=2.73; 95% CI, 1.10‑6.78), low cytoplasmic PTEN protein expression levels (P=0.017; HR=3.29; 95% CI, 1.24‑8.73) and high cytoplasmic pAkt^Ser473 protein expression levels (P=0.027; HR=2.64; 95% CI, 1.12‑6.23) remained significant in the multivariate analysis. Kaplan‑Meier survival analysis showed that high T stage, metastasis, low expression levels of cytoplasmic PTEN protein and high expression levels of cytoplasmic pAkt^Ser473 protein were significantly associated with poor survival (P=0.006, 0.001, 0.011 and 0.014, respectively). Co‑expression of PTEN^low/pAkt^Ser473/high and pAkt^Thr308/high phenotypes was associated with a less favorable overall survival (P=0.001). Overall, the present findings demonstrated that low expression levels of PTEN and high expression levels of pAkt^Ser473 and pAkt^Thr308 were predictors for poor overall survival in patients with UTUC.

View Figures

View References

1	Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
3	Verhoest G, Shariat SF, Chromecki TF, Raman JD, Margulis V, Novara G, Seitz C, Remzi M, Rouprêt M, Scherr DS and Bensalah K: Predictive factors of recurrence and survival of upper tract urothelial carcinomas. World J Urol. 29:495–501. 2011. View Article : Google Scholar : PubMed/NCBI
4	Lai MN, Wang SM, Chen PC, Chen YY and Wang JD: Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst. 102:179–186. 2010. View Article : Google Scholar : PubMed/NCBI
5	Taiwan Health Promotion Administration Ministry of Health and Welfare Taiwan, . Cancer Registry Annual Report, 2014 Taiwan. 1212016.
6	Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Böhle A, Van Rhijn BW, Kaasinen E, et al: European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 Update. Eur Urol. 68:868–879. 2015. View Article : Google Scholar : PubMed/NCBI
7	Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y, Remzi M, Bolenz C, Langner C, Weizer A, et al: Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol. 27:612–618. 2009. View Article : Google Scholar : PubMed/NCBI
8	Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
9	Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, et al: Colorectal cancer: Mutations in a signalling pathway. Nature. 436:7922005. View Article : Google Scholar : PubMed/NCBI
10	Cordes I, Kluth M, Zygis D, Rink M, Chun F, Eichelberg C, Dahlem R, Fisch M, Höppner W, Wagner W, et al: PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer. Histopathology. 63:670–677. 2013.PubMed/NCBI
11	Chalhoub N and Baker SJ: PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009. View Article : Google Scholar : PubMed/NCBI
12	Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, Holmes AB, McCormick F and Hawkins PT: Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science. 277:567–570. 1997. View Article : Google Scholar : PubMed/NCBI
13	Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
14	Sabatini DM: mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer. 6:729–734. 2006. View Article : Google Scholar : PubMed/NCBI
15	Hay N: The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 8:179–183. 2005. View Article : Google Scholar : PubMed/NCBI
16	Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade C, Attal M, Payrastre B, Demur C and Récher C: The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia. 23:1029–1038. 2009. View Article : Google Scholar : PubMed/NCBI
17	Freudlsperger C, Horn D, Weißfuß S, Weichert W, Weber KJ, Saure D, Sharma S, Dyckhoff G, Grabe N, Plinkert P, et al: Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma. Int J Cancer. 136:2775–2785. 2015. View Article : Google Scholar : PubMed/NCBI
18	Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB and Phillips WA: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64:7678–7681. 2004. View Article : Google Scholar : PubMed/NCBI
19	Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A and Bartlett JM: AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol. 207:139–146. 2005. View Article : Google Scholar : PubMed/NCBI
20	Okano J, Snyder L and Rustgi AK: Genetic alterations in esophageal cancer. Methods Mol Biol. 222:131–145. 2003.PubMed/NCBI
21	Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL and Reddy SA: The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene. 23:8571–8580. 2004. View Article : Google Scholar : PubMed/NCBI
22	Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD and Yan H: Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 64:5048–5050. 2004. View Article : Google Scholar : PubMed/NCBI
23	Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 441:424–430. 2006. View Article : Google Scholar : PubMed/NCBI
24	Knowles MA, Platt FM, Ross RL and Hurst CD: Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev. 28:305–316. 2009. View Article : Google Scholar : PubMed/NCBI
25	Courtney KD, Corcoran RB and Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol. 28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
26	Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF and Knowles MA: AKT1 mutations in bladder cancer: Identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene. 29:150–155. 2010. View Article : Google Scholar : PubMed/NCBI
27	Brognard J, Clark AS, Ni Y and Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61:3986–3997. 2001.PubMed/NCBI
28	Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, et al: Bladder cancer. J Natl Compr Canc Netw. 11:446–475. 2013. View Article : Google Scholar : PubMed/NCBI
29	Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester R, Burger M, Cowan N, Böhle A, Van Rhijn BW, Kaasinen E, et al: European guidelines on upper tract urothelial carcinomas: 2013 Update. Eur Urol. 63:1059–1071. 2013. View Article : Google Scholar : PubMed/NCBI
30	Edge SB and Compton CC: The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
31	Weng WH, Ahlén J, Aström K, Lui WO and Larsson C: Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res. 11:6198–6204. 2005. View Article : Google Scholar : PubMed/NCBI
32	Gonzalez-Roibon ND, Chaux A, Al-Hussain T, Osunkoya AO, Bezerra SM, Hicks J, Epstein JI and Netto GJ: Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder. Hum Pathol. 44:612–622. 2013. View Article : Google Scholar : PubMed/NCBI
33	Rieken M, Shariat SF, Karam JA, Foerster B, Khani F, Gust K, Abufaraj M, Wood CG, Weizer AZ, Raman JD, et al: Frequency and prognostic value of PTEN loss in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol. 198:1269–1277. 2017. View Article : Google Scholar : PubMed/NCBI
34	Qian CN, Furge KA, Knol J, Huang D, Chen J, Dykema KJ, Kort EJ, Massie A, Khoo SK, Vanden Beldt K, et al: Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: Identification in human tumors and confirmation in animal models. Cancer Res. 69:8256–8264. 2009. View Article : Google Scholar : PubMed/NCBI
35	Munari E, Fujita K, Faraj S, Chaux A, Gonzalez-Roibon N, Hicks J, Meeker A, Nonomura N and Netto GJ: Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma. Hum Pathol. 44:2668–2676. 2013. View Article : Google Scholar : PubMed/NCBI
36	Makboul R, Refaiy A, Abdelkawi IF, Hameed DA, Elderwy AA, Shalaby MM, Merseburger AS and Hussein MR: Alterations of mTOR and PTEN protein expression in schistosomal squamous cell carcinoma and urothelial carcinoma. Pathol Res Pract. 212:385–392. 2016. View Article : Google Scholar : PubMed/NCBI
37	Tsuruta H, Kishimoto H, Sasaki T, Horie Y, Natsui M, Shibata Y, Hamada K, Yajima N, Kawahara K, Sasaki M, et al: Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res. 66:8389–8396. 2006. View Article : Google Scholar : PubMed/NCBI
38	Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P and Knowles MA: Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 15:6008–6017. 2009. View Article : Google Scholar : PubMed/NCBI
39	Koletsas N, Koletsa T, Choidas S, Anagnostopoulos K, Touloupidis S, Zaramboukas T, Raptou G, Papadopoulos N and Lambropoulou M: Immunohistochemical investigation of HER/AKT/mTOR pathway and cellular adhesion molecules in urothelial carcinomas. Patholog Res Int. 2017:67941502017.PubMed/NCBI
40	Brugge J, Hung MC and Mills GB: A new mutational AKTivation in the PI3K pathway. Cancer Cell. 12:104–107. 2007. View Article : Google Scholar : PubMed/NCBI
41	Franke TF, Kaplan DR, Cantley LC and Toker A: Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science. 275:665–668. 1997. View Article : Google Scholar : PubMed/NCBI
42	Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S and Ghosh PM: Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 64:5232–5236. 2004. View Article : Google Scholar : PubMed/NCBI
43	Vincent EE, Elder DJ, Thomas EC, Phillips L, Morgan C, Pawade J, Sohail M, May MT, Hetzel MR and Tavaré JM: Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br J Cancer. 104:1755–1761. 2011. View Article : Google Scholar : PubMed/NCBI
44	Shin E, Choi CM, Kim HR, Jang SJ and Park YS: Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma. Lung Cancer. 89:13–18. 2015. View Article : Google Scholar : PubMed/NCBI
45	Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner R, et al: Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 61:818–825. 2012. View Article : Google Scholar : PubMed/NCBI
46	Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD and Wood CG; Upper Tract Urothelial Carcinoma CollaborationThe Upper Tract Urothelial Carcin, : Outcomes of radical nephroureterectomy: A series from the upper tract urothelial carcinoma collaboration. Cancer. 115:1224–1233. 2009. View Article : Google Scholar : PubMed/NCBI
47	Ehdaie B, Chromecki TF, Lee RK, Lotan Y, Margulis V, Karakiewicz PI, Novara G, Raman JD, Ng C, Lowrance WT, et al: Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma. J Urol. 186:66–72. 2011. View Article : Google Scholar : PubMed/NCBI
48	Izquierdo L, Truan D, Mengual L, Mallofré C and Alcaraz A: HER-2/AKT expression in upper urinary tract urothelial carcinoma: Prognostic implications. Anticancer Res. 30:2439–2445. 2010.PubMed/NCBI
49	Wheat JC, Weizer AZ, Wolf JS Jr, Lotan Y, Remzi M, Margulis V, Wood CG, Montorsi F, Roscigno M, Kikuchi E, et al: Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urol Oncol. 30:252–258. 2012. View Article : Google Scholar : PubMed/NCBI
50	Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, Weng WH, Siew EY, Liu Y, Heng HL, et al: Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med. 5:197ra1012013. View Article : Google Scholar : PubMed/NCBI